Use: Labeled indications
- to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia…
- . to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible
Full indications and usage US FDA label
1 INDICATIONS AND USAGE LIPOFEN is indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. LIPOFEN is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL) (1). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible (1) Limitations of Use: Markedly elevated levels of serum TG (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis.
The effect of fenofibrate therapy on reducing this risk has not been determined (1). Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus. (1) Limitations of Use Markedly elevated levels of serum TG (e.g., ≥ 2,000 mg/dL) may increase the risk of developing pancreatitis.
The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7)]. Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1) and Clinical Studies (14.4)].
Contraindications
4 CONTRAINDICATIONS LIPOFEN is contraindicated in patients with: Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3)]. Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].
Pre-existing gallbladder disease [see Warnings and Precautions (5.5)]. Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in LIPOFEN. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions (5.9)]. Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis (4) Active liver disease, including those with unexplained persistent liver function abnormalities (4) Pre-existing gallbladder disease (4) Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in LIPOFEN (4)
US FDA labelDosing: Adult
- Severe hypertriglyceridemia: 50 to 150 mg orally once daily; the dosage should be adjusted according to patient response (2.2)
- Primary hyperlipidemia: 150 mg orally once daily (2.2)
- Administer as a single dose, at any time of day, with food 2.2). Assess TG when clinically appropriate, as early as 4 to 8 weeks after initiating LIPOFEN. Discontinue LIPOFEN in patients who do not have an adequate response after 2 months of treatment (2.2)
- Renal impairment: Initial dosage of 50 mg orally once daily (2.3)
- Geriatric patients: Select the dosage on the basis of renal function (2.4)
2.1 Prior to Initiation
2.1 Prior to Initiation of LIPOFEN Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high TG levels and manage as appropriate. Patients should be placed on an appropriate lipid-lowering diet before receiving LIPOFEN, and should continue this diet during treatment with LIPOFEN.
In patients with diabetes and fasting chylomicronemia, improve glycemic control prior to considering starting LIPOFEN.
2.2 Recommended Dosage and Administration
2.2 Recommended Dosage and Administration Severe hypertriglyceridemia: The recommended dosage of LIPOFEN is 50 mg or 150 mg orally once daily. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. Primary hyperlipidemia: The recommended dosage of LIPOFEN is 150 mg orally once daily.
Administer LIPOFEN as a single dose at any time of day, with food. Advise patients to swallow LIPOFEN capsules whole. Do not crush, break, dissolve, or chew capsules. Assess TG when clinically appropriate, as early as 4 to 8 weeks after initiating LIPOFEN. Discontinue LIPOFEN in patients who do not have an adequate response after 2 months of treatment.
If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose. Advise patients to take LIPOFEN at least 1 hour before or 4 hours to 6 hours after a bile acid binding resin to avoid impeding its absorption.
2.3 Recommended Dosage in Patients with Renal Impairment
2.3 Recommended Dosage in Patients with Renal Impairment Assess renal function prior to initiation of LIPOFEN and periodically thereafter [see Warnings and Precautions (5.4)]. Treatment with LIPOFEN should be initiated at a dosage of 50 mg orally once daily in patients with mild to moderately impaired renal function (eGFR 30 to <60 mL/min/1.73 m²), and increased only after evaluation of the effects on renal function and TG levels at this dosage.
LIPOFEN is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), including those with end-stage renal disease (ESRD) and those receiving dialysis [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
2.4 Recommended Dosage in Geriatric Patients
2.4 Recommended Dosage in Geriatric Patients Dosage selection for geriatric patients should be made on the basis of renal function [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
2.3 Recommended Dosage in Patients with Renal Impairment Assess renal function prior to initiation of LIPOFEN and periodically thereafter [see Warnings and Precautions (5.4)]. Treatment with LIPOFEN should be initiated at a dosage of 50 mg orally once daily in patients with mild to moderately impaired renal function (eGFR 30 to <60 mL/min/1.73 m²), and increased only after evaluation of the effects on renal function and TG levels at this dosage.
LIPOFEN is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), including those with end-stage renal disease (ESRD) and those receiving dialysis [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
8.6 Renal Impairment LIPOFEN is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) including those with end-stage renal disease (ESRD) and those receiving dialysis. Dosage reduction is required in patients with mild to moderate renal impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
Patients with severe renal impairment have 2.7-fold higher exposure of fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared with healthy volunteers. Renal impairment is a risk factor for myopathy and rhabdomyolysis [see Warnings and Precautions (5.3, 5.4), and Clinical Pharmacology (12.3)].
Patients with Renal Impairment The pharmacokinetics of fenofibric acid were examined in patients with mild, moderate and severe renal impairment.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment The use of LIPOFEN has not been evaluated in patients with hepatic impairment. LIPOFEN is contraindicated in patients with active liver disease, including those with unexplained persistent liver function abnormalities [Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of LIPOFEN have not been established in pediatric patients with severe hypertriglyceridemia or primary hyperlipidemia.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Assess renal function in geriatric patients and follow contraindications and dosing recommendations for patients with renal impairment [see Contraindications (4), Warnings and Precautions (5.3, 5.4), and Use in Specific Populations (8.6). While fenofibric acid exposure is not influenced by age, geriatric patients are more likely to have renal impairment, and fenofibric acid is substantially excreted by the kidney [see Clinical Pharmacology (12.3)]. Consider monitoring renal function in geriatric patients taking LIPOFEN.
Administration
2.2 Recommended Dosage and Administration Severe hypertriglyceridemia: The recommended dosage of LIPOFEN is 50 mg or 150 mg orally once daily. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. Primary hyperlipidemia: The recommended dosage of LIPOFEN is 150 mg orally once daily. Administer LIPOFEN as a single dose at any time of day, with food. Advise patients to swallow LIPOFEN capsules whole. Do not crush, break, dissolve, or chew capsules. Assess TG when clinically appropriate, as early as 4 to 8 weeks after initiating LIPOFEN. Discontinue LIPOFEN in patients who do not have an adequate response after 2 months of treatment. If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose. Advise patients to take LIPOFEN at least 1 hour before or 4 hours to 6 hours after a bile acid binding resin to avoid impeding its absorption.
US FDA labelDosage forms
Philippines
- Capsule: 67 mg, 100 mg, 160 mg, 200 mg, 300 mg
- Micronized capsule: 160 mg, 200 mg
- Film-coated tablet: 145 mg, 160 mg
- Tablet: 160 mg
- Micronised capsule: 200 mg
- Micronized tablet: 160 mg
- Sustained-release capsule: 250 mg
Registered products in the Philippines
133 products registered with the Food and Drug Administration (FDA) Philippines list Fenofibrate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products133
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AudraFenofibrate | 160 mg TabletAlu-PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-13693-01 | Apr 13, 2028 | |
Audra-160Fenofibrate | 160 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-6713 | Jun 6, 2031 | |
BerafenFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Mc Graw Pharma Inc.Importer: Ambica International Corporation | DRP-4070-02 | Oct 19, 2027 | |
CholefenFenofibrate | 200 mg CapsuleAlu/Strip Foil x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: D.B. Manix International, Inc. | DRP-5318 | Sep 7, 2031 | |
CholefenFenofibrate | 300 mg CapsuleStrip Foil x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: D.B. Manix International, Inc. | DR-XY32986 | Feb 12, 2027 | |
CholefixFenofibrate | 160 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Pharmakon Biotec Inc. | DRP-6713-09 | Jun 6, 2031 | |
DectriFenofibrate | 160 mg TabletAlu-PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-13693 | Apr 13, 2028 | |
DiafenoFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Aristo Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4070-01 | Oct 19, 2027 | |
ExcelfinFenofibrate | 160 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | 288 Pharma TradingImporter: Pharmakon Biotec Inc. | DRP-6713-03 | Jun 6, 2036 | |
Fencap-FCFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | F.C. Andres Drug DistributorImporter: Ambica International Corporation | DRP-4070-10 | Oct 19, 2027 | |
FenetorFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4070-15 | Oct 19, 2027 | |
FenfifixxFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4070-08 | Oct 19, 2027 | |
FennotolFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-4070-13 | Oct 19, 2027 | |
FennotolFenofibrate | 200 mg Micronized CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambicare Pharmaceuticals Inc.Trader: Athena Pharmaceutique SAS | DRP-16872-02 | Jul 31, 2030 | |
Feno-TGFenofibrate | 160mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Troikaa Pharmaceuticals Ltd.India | Troikaa Pharmaceuticals Philippines, Inc. | DRP-8342 | Sep 11, 2027 | |
FenobetFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-6162-02 | Feb 10, 2028 | |
FenoblastFenofibrate | 160 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | I.E. Medica, Inc. | DRP-1391 | Apr 23, 2029 | |
FenobritFenofibrate | 100 mg CapsuleAlu/PVC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-5044 | Jan 7, 2029 | |
FenobritFenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4839 | Oct 16, 2028 | |
FenobritFenofibrate | 200 mg CapsuleAlu/ Clear PVC Blister Pack x 10's Box of 30's, 50's and 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4838 | Oct 16, 2028 | |
FenobritFenofibrate | 300 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4830 | Oct 16, 2028 | |
FenobritFenofibrate | 67 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's); Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-5043 | Jan 7, 2029 | |
FenocareFenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | REGIMED PHARMACEUTICAL DISTRIBUTOR | DRP-4838-05 | Oct 16, 2028 | |
FenoceedFenofibrate | 100 mg CapsuleAlu / PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | CDMED Pharmaceutical and Medical Supply | DRP-5044-07 | Jan 7, 2029 | |
FenoceedFenofibrate | 160 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | CDMED Pharmaceutical And Medical Supply | DRP-4839-09 | Oct 16, 2028 | |
FenoceedFenofibrate | 200 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | CDMed Pharmaceutical and Medical Supply | DRP-4838-08 | Oct 16, 2028 | |
FenocholFenofibrate | 200 mg CapsuleAlu/Poly Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-18323 | Jun 11, 2031 | |
FenocronFenofibrate | 160 mg Micronized CapsuleAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Flourish PharmaIndia | Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-16092 | Oct 30, 2029 | |
Fenocron-200Fenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Flourish PharmaIndia | Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-18373 | Jun 24, 2031 | |
FenofadzFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Fadz Pharma Inc.Importer: Ambica International Corporation | DRP-4070-11 | Oct 19, 2027 | |
FenofastFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Meedpharma Medical Supplies & Equipment DistributorImporter: Ambica International Corporation | DRP-4070 | Oct 19, 2027 | |
FenoferFenofibrate | 160 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Bulacan | Ferma Drug Enterprises | DRP-4839-13 | Oct 16, 2028 | |
Fenofillen-B160Fenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | RxVAT-exempt | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18462 | Jul 27, 2031 | |
Fenofillen-B200Fenofibrate | 200 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18463 | Jul 27, 2031 | |
FenoflexFenofibrate | 160 mg CapsuleAlu/Alu Flex Foil Strip x 6's (Box of 30's) | RxVAT-exempt | PT Darya-Varia Laboratoria Tbk.Indonesia | UNILAB, Inc. | DRP-13382 | Feb 15, 2028 | |
FenoflexFenofibrate | 160 mg CapsuleAlu/Alu Blister Pack x 6's Box of 30's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-9976 | Oct 31, 2027 | |
FenogalFenofibrate | 160 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | S.M.B. TECHNOLOGY S.A.Belgium | BRITTON DISTRIBUTIONS, INC. | DR-XY33277 | May 4, 2027 | |
FenogenFenofibrate | 160 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-4839-08 | Oct 16, 2028 | |
FenogenFenofibrate | 200 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-4838-07 | Oct 16, 2028 | |
FenogenFenofibrate | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC. | DRP-4830-02 | Oct 16, 2028 | |
FenogenFenofibrate | 67 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-5043-02 | Jan 7, 2029 | |
FenokFenofibrate | 100 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-5044-05 | Jan 7, 2029 | |
FenokFenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience And Drug Store Corp. | DRP-4839-06 | Oct 16, 2028 | |
FenokFenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-4838-06 | Oct 16, 2028 | |
FenokFenofibrate | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-4830-03 | Oct 16, 2028 | |
FenokFenofibrate | 67 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience and Drug Store Corp. | DRP-5043-03 | Jan 7, 2029 | |
FenolitFenofibrate | 200 mg CapsuleAlu-foil strip x 10's (Box of 3 foil strips x 10 capsules) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Littman Drug Corporation | DR-XY33626 | Mar 24, 2028 | |
FenolizenFenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Hale Medipoint Corp. | DRP-4839-10 | Oct 16, 2028 | |
FenolizenFenofibrate | 200 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Hale Medipoint Corp. | DRP-4838-10 | Oct 16, 2028 | |
FenomelFenofibrate | 100 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-5044-06 | Jan 7, 2029 | |
FenomelFenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-4839-11 | Oct 16, 2028 | |
FenomelFenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-4838-09 | Oct 16, 2028 | |
FenomelFenofibrate | 300 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-4830-04 | Oct 16, 2028 | |
FenomelFenofibrate | 67 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-5043-04 | Jan 7, 2029 | |
FenoprimeFenofibrate | 145 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hetero Labs LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: Camber Pharmaceuticals, Inc. | DRP-11646-02 | Oct 3, 2029 | |
FenopsivFenofibrate | 200 mg capsuleAlu Strip Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Vispomed CorporationTrader: Westfield Pharmaceuticals, Inc. | DRP-17561-01 | May 5, 2027 | |
FenorenFenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Bulacan | One Health Marketing Inc. | DRP-4838-12 | Oct 16, 2028 | |
FenorichFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Medirich Pharma Distribution Corp.Importer: Orange Biotec Inc. | DRP-6162-04 | Feb 10, 2028 | |
FenorixFenofibrate | 200 mg Micronized CapsuleAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15182 | May 21, 2029 | |
FenorixFenofibrate | 200mg CapsuleAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12280 | Jul 7, 2027 | |
Fenosaph-160Fenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences Inc. | DRP-12257 | Sep 9, 2030 | |
Fenosaph-200Fenofibrate | 200 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 30's, 50’s and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: N/A | DRP-10930 | Jun 24, 2032 | |
FenosolFenofibrate | 100 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-5044-03 | Jan 7, 2029 | |
FenosolFenofibrate | 160 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4839-03 | Oct 16, 2028 | |
FenosolFenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4838-03 | Oct 16, 2028 | |
FenosolFenofibrate | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4830-01 | Oct 16, 2028 | |
FenosynFenofibrate | 200 mg CapsuleAlu-PVC Clear Blister x 10’s (Box of 100’s) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | N/A | DRP-12589 | Sep 12, 2027 | |
FenoxedFenofibrate | 200 mg Micronized CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s, Box of 50's and 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10930-01 | Jan 18, 2027 | |
Fenozan-160Fenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical and Pharma Inc. | DRP-4839-12 | Oct 16, 2028 | |
Fenozan-200Fenofibrate | 200 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-4838-11 | Oct 16, 2028 | |
Fensaph-G160Fenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Global Pharma Healthcare Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17047 | Sep 15, 2030 | |
Fensaph-G200Fenofibrate | 200 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Global Pharma Healthcare Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17046 | Sep 15, 2030 | |
Fib-ColFenofibrate | 200 mg CapsuleAlu/Strip Foil x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Ultramed Pharma, Inc.Trader: D.B. Manix International, Inc. | DRP-5318-02 | Sep 7, 2031 | |
Fibrafen 200MFenofibrate | 200 mg Micronised CapsuleAlu/PVC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Astrea FontaineFrance | Zuellig Pharma CorporationImporter: Abbott LaboratoriesTrader: Laboratoires Fournier S.A.S. | DRP-125 | Mar 30, 2031 | |
FibralifeFenofibrate | 200 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Innovative HealthcareIndia | Biophil Medical Equipment and Supplies Trading | DRP-18213 | Jun 2, 2031 | |
FibrenFenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Innovative HealthcareIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-18214 | Jun 2, 2031 | |
Fibrix 160Fenofibrate | 160 mg Film-Coated TabletAlu/PVC Blister Pack x 10 (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Alpha Farmaceutico Corp.Importer: Pharmakon Biotec Inc. | DRP-6713-10 | Jun 6, 2036 | |
Fibrofin 145Fenofibrate | 145 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-11646 | Oct 3, 2029 | |
FinofenFenofibrate | 200 mg CapsuleAlu/PVC Blister Pack x 10' s (Box of 30' s) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentina | Medinova Pharmaceutical Inc. | DRP-14149 | Jun 30, 2028 | |
FinoraFenofibrate | 200 mg CapsuleAlu/PVC-PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Trumed PharmaceuticalsImporter: AMB HK Enterprises, Inc. | DRP-12280-01 | Jul 7, 2027 | |
GofibraFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution, Inc.Importer: Ambica International Corporation | DRP-4070-05 | Oct 19, 2027 | |
InofibFenofibrate | 300 mg CapsuleStrip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY32985 | Feb 12, 2027 | |
InofibFenofibrate | 300 mg CapsuleStrip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-12878 | Feb 12, 2027 | |
LipanthylFenofibrate | 67 mg CapsulePVC/Alu Blister Pack x 12's (Box of 36's) | RxVAT-exempt | Astrea FontaineFrance | Zuellig Pharma CorporationImporter: Abbott LaboratoriesTrader: Laboratoires Fournier S.A.S. | DR-XY26190 | Feb 25, 2031 | |
Lipanthyl NTFenofibrate | 145 mg Film-Coated Tablet | RxVAT-exempt | Abbott Healthcare Private LimitedIndia | Zuellig Pharma CorporationImporter: Abbott LaboratoriesTrader: Laboratoires Fournier S.A.S. | DR-XY33285 | Feb 10, 2031 | |
Lipanthyl SupraFenofibrate | 160 mg Film-Coated TabletThermoformed PVC/PE/PVDC-Alu Blister Strip x 10's (Box of 30's) | RxVAT-exempt | Recipharm FontaineFrance | Zuellig Pharma CorporationImporter: Abbott LaboratoriesTrader: Laboratoires Fournier S.A.S. | DRP-122 | Jun 5, 2027 | |
LipibrateFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Macizzo EnterprisesImporter: Ambica International Corporation | DRP-4070-07 | Oct 19, 2027 | |
Lipid-AidFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Rule Med Pharma Corp.Importer: Suhitas Pharmaceuticals Inc | DRP-6162-03 | Feb 10, 2028 | |
LipidaceFenofibrate | 200 mg CapsuleAlu/Strip Foil x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | HEI Gruppo Pharmaceutica, Inc.Trader: D.B. Manix International, Inc. | DRP-5318-01 | Aug 27, 2031 | |
Lipiduce 160Fenofibrate | 160 mg Film-coated TabletAlu-Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY44833 | Sep 21, 2030 | |
LipiridFenofibrate | 200 mg capsuleAlu/Clear PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Pei li Pharmaceutical Ind.Co., LtdTaiwan | Neo care Philippines | DR-XY43880 | Nov 17, 2029 | |
LipwayFenofibrate | 160 mg TabletAlu/Alu Strip Foil x 6's (Box of 30's) | RxVAT-exempt | EL Laboratories, Inc.Philippines | Trader: The Cathay Drug Co., Inc. | DR-XY44257 | Mar 19, 2030 | |
Lipway SRFenofibrate | 250 mg Sustained-Release CapsuleBlister Pack x 10's Box of 30's | RxVAT-exempt | SWISSPHARMA RESEARCH LABORATORIES, INC.Philippines | Trader: THE CATHAY DRUG COMPANY, INC. | DR-XY28840 | Jul 29, 2028 | |
LofibraFenofibrate | 200 mg CapsuleBlister pack x 10's Box of 50's | RxVAT-exempt | Micro Labs Limited (Unit III)India | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-7250 | Jan 4, 2029 | |
LotrilipFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-6162 | Feb 10, 2028 | |
Macfibrate 145Fenofibrate | 145 mg Film-Coated TabletAlu Clear PVC/PVDC Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY48870 | Sep 12, 2028 | |
NoneFenofibrate | 160 mg Film Coated TabletAlu / PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Troikaa Pharmaceuticals Ltd.India | South Star DrugImporter: Troikaa Pharmaceuticals Philippines Inc. | DRP-8342-01 | Sep 11, 2027 | |
NoneFenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack of 10’s (Box of 100’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12257-02 | Jul 5, 2027 | |
NoneFenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister pack x 10’s (Box of 100’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Watsons Personal Care Store (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12257-03 | Jul 5, 2027 | |
NoneFenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12257-04 | Jul 5, 2027 | |
NoneFenofibrate | 160 mg Micronized CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | PharmaVital Corp.Importer: Nelpa Lifesciences Inc. | DRP-12257-05 | Sep 9, 2030 | |
NoneFenofibrate | 160 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-1391-02 | Apr 23, 2028 | |
NoneFenofibrate | 200 mg CapsuleAlu Strip Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-17561 | May 5, 2027 | |
NoneFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4070-03 | Oct 19, 2027 | |
NoneFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | TGP Pharma, Inc.Importer: Ambica International Corporation | DRP-4070-06 | Oct 19, 2027 | |
NoneFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-4070-12 | Oct 19, 2027 | |
NoneFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | K Pharma Medical Corp.Importer: Ambica International Corporation | DRP-4070-14 | Oct 19, 2027 | |
NoneFenofibrate | 200 mg Micronized CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | PharmaVital Corp.Importer: Ambicare Pharmaceuticals Inc.Trader: Athena Pharmaceutique SAS | DRP-16872-01 | Jul 31, 2030 | |
NoneFenofibrate | 200 mg Micronized CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Athena Pharmaceutique SAS | DRP-16872-03 | Jul 31, 2030 | |
PrimenofastFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's Box of 50's | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Ambica International Corporation | DRP-4070-04 | Oct 19, 2027 | |
Q-DipilsFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-4070-09 | Oct 19, 2027 | |
Retafebril 160Fenofibrate | 160 mg TabletAlu-PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals Inc. | DRP-13693-02 | Apr 13, 2028 | |
SydenfenFenofibrate | 200 mg CapsuleAlu-PVC Clear Blister x 10’s (Box of 100’s) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | N/A | DRP-12588 | Sep 12, 2027 | |
TrichekFenofibrate | 200 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-6162-01 | Feb 10, 2028 | |
TridenFenofibrate | 160 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceuticals Industries LimitedIndia | EMCURE PHARMA PHILIPPINES INC.Importer: I.E. Medica, Inc | DRP-1391-03 | Apr 23, 2029 | |
TridenFenofibrate | 160 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Athena Drug Delivery Pvt., Ltd.India | Emcure Pharma Philippines Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Athena Pharmaceutique SAS | DRP-16873-01 | Jul 31, 2030 | |
TripibraFenofibrate | 100 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-5044-02 | Jan 7, 2029 | |
TripibraFenofibrate | 160 mg CapsuleAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-4839-07 | Oct 16, 2028 | |
TripibraFenofibrate | 200mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4838-02 | Oct 16, 2028 | |
TrolipFenofibrate | 160 mg Film-Coated TabletPolycellonium strip pack x 6's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Glorious Dexa Mandaya Inc. | DRP-15653 | Aug 15, 2029 | |
TrolipFenofibrate | 300 mg CapsuleBlister Pack x 10's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Importer: Glorious Dexa Mandaya, Inc. | DR-XY27805 | Sep 4, 2027 | |
TrolipFenofibrate | 300 mg CapsuleBlister Pack x 10's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Importer: Glorious Dexa Mandaya, Inc. | DRP-11529 | Sep 4, 2027 | |
UnbrandedFenofibrate | 100mg CapsuleBlister pack x 20's (Box of 60's) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-3966 | Oct 30, 2030 | |
UnbrandedFenofibrate | 160 mg Film-Coated TabletAlu/PVC Blister Pack x 10 (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-6713-06 | Jun 6, 2036 | |
UnbrandedFenofibrate | 160 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's Box of 100's | RxVAT-exempt | Sun Pharmaceuticals Industries LimitedIndia | TGP Pharma Inc.Importer: I.E. Medica, Inc. | DRP-1391-01 | Apr 23, 2029 | |
UnbrandedFenofibrate | 200 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentine Republic | Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc. | DRP-14149-01 | Jun 30, 2028 | |
Vanfibra 160Fenofibrate | 160 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Ambicare Pharmaceuticals Inc. | DRP-16873 | Jul 31, 2030 | |
Vanfibra 200Fenofibrate | 200 mg Micronized CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd. PlotIndia | Ambicare Pharmaceuticals Inc. | DRP-16872 | Jul 31, 2030 | |
Zinof 200Fenofibrate | 200 mg CapsulePVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Bell-Kenz Pharma Inc. | DRP-3511 | Jan 19, 2027 | |
Zinof 200Fenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6547 | Sep 3, 2029 | |
(no brand name)Fenofibrate | 160 mg Micronized TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Ritemed Phils., Inc. | DRP-17179 | Oct 16, 2030 | |
(no brand name)Fenofibrate | 200 mg CapsuleAlu Strip Pack x 10's (Box of 30's) Manufacturer | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY48000 | May 5, 2027 | |
(no brand name)Fenofibrate | 200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Athena Drug Delivery Solutions Pvt. Ltd.India | Ritemed Phils., Inc. | DRP-11555 | Mar 29, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 50 mg: Size 3 white opaque gelatin capsule imprinted "G 246" and "50" in black ink. 150 mg: Size 1 white opaque gelatin capsule imprinted "G 248" and "150" in green ink. Capsules: 50 mg and 150 mg (3)
Warnings/Precautions
- Hepatotoxicity: Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrates, including LIPOFEN. Monitor patient's liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy. Discontinue if signs or symptoms of liver injury develop or if elevated enzyme levels persist. (5.2)
- Myopathy and Rhabdomyolysis: Have been reported in patients taking fenofibrates. Risks are increased during co-administration with a statin, in geriatric patients and in patients with renal impairment, or hypothyroidism. Discontinue LIPOFEN if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Temporarily discontinue LIPOFEN in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the LIPOFEN dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.3)
- Increases in Serum Creatinine: Monitor renal function in patients with renal impairment taking LIPOFEN. Consider monitoring renal function in patients at risk for renal impairment. (5.4)
- Cholelithiasis: Fenofibrate may increase cholesterol excretion into the …
5.1 Mortality and Coronary Heart Disease Morbidity
5.1 Mortality and Coronary Heart Disease Morbidity Fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus [see Clinical Studies (14.4)]. Because of chemical, pharmacological, and clinical similarities between fenofibrates, including LIPOFEN; pemafibrate; clofibrate; and gemfibrozil; the findings in 5 large randomized, placebo-controlled clinical trials with these other fibrate drugs may also apply to LIPOFEN.
Pemafibrate did not reduce cardiovascular disease morbidity or mortality in a large, randomized, placebo-controlled trial of patients with type 2 diabetes mellitus on background statin therapy [see Clinical Studies (14.4)]. In the Coronary Drug Project, a large trial conducted from 1965 to 1985 in men post myocardial infarction, there was no difference in mortality or nonfatal myocardial infarction between the clofibrate group and the placebo group after 5 years of treatment (NCT00000482).
In a trial conducted by the World Health Organization (WHO) from 1965 to 1976, men without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional 1 year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p≤0.01).
Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. The Helsinki Heart Study, conducted from 1982 to 1987, was a large (n=4,081) trial of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5-year open extension afterward.
Total mortality was numerically but not statistically higher in the gemfibrozil randomization group versus placebo [95% confidence interval (CI) of the hazard ratio (HR) 0.91 to 1.64]. A secondary prevention component of the Helsinki Heart Study treated middle-aged men with gemfibrozil or placebo for 5 years. The HR for cardiac deaths was 2.2, 95% CI, 0.94 to 5.05.
5.2 Hepatotoxicity
5.2 Hepatotoxicity Serious drug-induced liver injury (DILI), including liver transplantation and death, has been reported with postmarketing use of fenofibrates, including LIPOFEN. DILI has been reported within the first few weeks of treatment or after several months of therapy and in some cases has reversed with discontinuation of LIPOFEN treatment.
Patients with DILI have experienced signs and symptoms including dark urine, abnormal stool, jaundice, malaise, abdominal pain, myalgia, weight loss, pruritus, and nausea. Many patients had concurrent elevations of total bilirubin, serum alanine transaminase (ALT), and aspartate transaminase (AST). DILI has been characterized as hepatocellular, chronic active, and cholestatic hepatitis, and cirrhosis has occurred in association with chronic active hepatitis.
In clinical trials, an intermediate daily dosage or the maximum recommended daily dosage of fenofibrate have been associated with increases in serum AST or ALT. The incidence of increases in transaminases may be dose related [see Adverse Reactions (6.1)]. LIPOFEN is contraindicated in patients with active liver disease, including those with unexplained persistent liver function abnormalities.
Monitor patient's liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy with LIPOFEN. Discontinue LIPOFEN if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST > 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).
Do not restart LIPOFEN in these patients if there is no alternative explanation for the liver injury.
5.3 Myopathy and Rhabdomyolysis
5.3 Myopathy and Rhabdomyolysis LIPOFEN may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Risk Factors for Myopathy Risk factors for myopathy include age 65 years or older, uncontrolled hypothyroidism, renal impairment, and concomitant use with certain other drugs [see Drug Interactions (7) and Use in Specific Populations (8.6)].
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis Data from observational studies indicate that the risk for rhabdomyolysis is increased when fibrates, including fenofibrates, are co-administered with a statin. Avoid concomitant use unless the benefit of further alterations in TG levels is likely to outweigh the increased risk of this drug combination [see Drug Interactions (7), Clinical Pharmacology (12.3), and Clinical Studies (14.4)].
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates, including LIPOFEN, co-administered with colchicine. Consider whether the benefit of using colchicine concomitantly with LIPOFEN outweighs the increased risk of myopathy [see Drug Interactions (7)]. Discontinue LIPOFEN if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected.
Muscle symptoms and CK elevations may resolve if LIPOFEN is discontinued. Temporarily discontinue LIPOFEN in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the LIPOFEN dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
5.4 Increases in Serum Creatinine
5.4 Increases in Serum Creatinine Increases in serum creatinine have been reported in patients receiving fenofibrates. These increases tend to return to baseline following discontinuation of LIPOFEN. The clinical significance of this finding is unknown. Monitor renal function in patients with renal impairment taking LIPOFEN.
Renal monitoring should also be considered for patients taking LIPOFEN at risk for renal insufficiency, such as geriatric patients and patients with diabetes. LIPOFEN is contraindicated in patients with severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Dosage and Administration (2.3), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
5.5 Cholelithiasis
5.5 Cholelithiasis Fenofibrate may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. LIPOFEN therapy should be discontinued if gallstones are found. LIPOFEN is contraindicated in patients with pre-existing gallbladder disease.
5.6 Increased Bleeding Risk with Coumarin Anticoagulants
5.6 Increased Bleeding Risk with Coumarin Anticoagulants Exercise caution when co-administering anticoagulants with LIPOFEN because of the potentiation of coumarin-type anticoagulant effects in prolonging the prothrombin time/International Normalized Ratio (PT/INR). To prevent bleeding complications, monitor the PT/INR frequently and adjust the dosage of the anticoagulant until the PT/INR has stabilized [see Drug Interactions (7)].
5.7 Pancreatitis
5.7 Pancreatitis Pancreatitis has been reported in patients taking fenofibrates. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.
5.8 Hematologic Changes
5.8 Hematologic Changes Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of therapy with fenofibrates. However, these levels stabilize during long-term administration. Thrombocytopenia and agranulocytosis have been reported in individuals treated with LIPOFEN.
Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of LIPOFEN administration.
5.9 Hypersensitivity Reactions Acute
5.9 Hypersensitivity Reactions Acute Hypersensitivity Anaphylaxis and angioedema have been reported with postmarketing use of fenofibrates. In some cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of an acute hypersensitivity reaction, advise them to seek immediate medical attention and discontinue LIPOFEN.
LIPOFEN is contraindicated in patients with a hypersensitivity to fenofibrate, fenofibric acid, or any of the ingredients in LIPOFEN. Delayed Hypersensitivity Severe cutaneous adverse drug reactions (SCAR), including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported with post-marketing use of fenofibrates, occurring days to weeks after treatment initiation.
The cases of DRESS were associated with cutaneous reactions (such as rash or exfoliative dermatitis) and a combination of eosinophilia, fever, systemic organ involvement (renal, hepatic, or respiratory). Discontinue LIPOFEN and treat patients appropriately if SCAR is suspected.
5.10 Venothromboembolic Disease
5.10 Venothromboembolic Disease In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, pulmonary embolus (PE) and deep vein thrombosis (DVT) were observed at higher rates in the fenofibrate than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group.
For DVT, there were 48 events (1%) in the placebo group and 67 (1.4%) in the fenofibrate group (p = 0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1.1%) in the fenofibrate group (p = 0.022). In the Coronary Drug Project, a higher proportion of the clofibrate group experienced definite or suspected fatal or nonfatal pulmonary embolism or thrombophlebitis than the placebo group (5.2% vs. 3.3% at five years; p<0.01).
In the cardiovascular outcome trial with pemafibrate, pulmonary embolism was reported for 37 (0.7%) subjects in the pemafibrate group and 16 (0.3%) subjects in the placebo group. Deep vein thrombosis was reported for 36 (0.7%) subjects in the pemafibrate group and 13 (0.2%) subjects in the placebo group.
5.11 Paradoxical Decreases in HDL Cholesterol Levels
5.11 Paradoxical Decreases in HDL Cholesterol Levels There have been postmarketing and clinical trial reports of severe decreases in high-density lipoprotein cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in patients with and without diabetes initiated on fibrate therapy, including fenofibrate. The decrease in HDL-C is mirrored by a decrease in apolipoprotein A1.
This decrease has been reported to occur within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is rapid and sustained. The clinical significance of this decrease in HDL-C is unknown. Check HDL-C levels within the first few months after initiation of LIPOFEN.
If a severely depressed HDL-C level is detected, discontinue LIPOFEN and monitor HDL-C until it has returned to baseline. LIPOFEN should not be re-initiated.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Table 2 presents clinically important drug interactions with LIPOFEN. Table 2: Clinically Important Drug Interactions with LIPOFEN Statins Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins. Intervention: Consider if the benefit of using LIPOFEN concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis.
If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with LIPOFEN outweighs the increased risk of myopathy and rhabdomyolysis.
If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of colchicine. Coumarin Anticoagulants Clinical Impact: Fibrates may cause potentiation of coumarin-type anticoagulant effects with prolongation of the PT/INR. Intervention: Caution should be exercised when coumarin anticoagulants are given in conjunction with LIPOFEN.
The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized. Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including LIPOFEN, there is a risk that an interaction will lead to deterioration of renal function.
Intervention: The benefits and risks of using LIPOFEN with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dosage employed and renal function monitored. Bile-Acid Binding Resins Clinical Impact: Bile-acid binding resins may bind other drugs given concurrently.
Intervention: In patients taking a bile acid resin, administer LIPOFEN at least 1 hour before or 4 to 6 hours after the bile acid resin to avoid impeding its absorption. Consider if the benefit of concomitant use of statins or colchicine outweighs the increased risk of myopathy and rhabdomyolysis. Monitor patients for signs and symptoms of myopathy (7) Exercise caution in concomitant treatment with coumarin anticoagulants.
Reduce the dosage of coumarin to maintain the PT/INR at the desired level to prevent bleeding complications (7). Consider the benefits and risks of concomitant use with immunosuppressants and other potentially nephrotoxic agents. Use the lowest effective dosage and monitor renal function (7). Administer LIPOFEN at least 1 hour before or 4 to 6 hours after a bile acid resin to avoid impeding its absorption (7).
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild to moderate inhibitors of CYP2C9 at therapeutic concentrations.
Adverse reactions
The following serious adverse reactions are described below and elsewhere in the labeling: Mortality and coronary heart disease morbidity [see Warnings and Precautions (5.1)] Hepatoxicity [see Warnings and Precautions (5.2)] Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.3)] Increases in Serum Creatinine [see Warnings and Precautions (5.4)] Cholelithiasis [see Warnings and Precautions (5.5)] Increased Bleeding Risk with Coumarin Anticoagulants [see Warnings and Precautions (5.6)] Pancreatitis [see Warnings and Precautions (5.7)] Hematologic Changes [see Warnings and Precautions (5.8)] Hypersensitivity reactions [see Warnings and Precautions (5.9)] Venothromboembolic disease [see Warnings and Precautions (5.10)] Paradoxical Decreases in HDL Cholesterol Levels [see Warnings and Precautions (5.11)] Adverse reactions (≥ 2% and greater than placebo): abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis (6.1). To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of LIPOFEN has been established in adults with hypertriglyceridemia or primary hyperlipidemia based on adequate and well-controlled trials of other formulations of fenofibrate, referenced below as "fenofibrate" [see Clinical Studies (14)].
Dosages of fenofibrate used in these trials were comparable to LIPOFEN 150 mg per day [see Clinical Pharmacology (12.3)]. Adverse reactions reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials are listed in Table 1 below. Adverse reactions led to discontinuation of treatment in 5% of patients treated with fenofibrate and in 3% treated with placebo.
Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials. Table 1: Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials Adverse Reaction Placebo (N =365) Fenofibrate (N = 439) Abnormal Liver Tests 1% 8% Abdominal Pain 4% 5% Increased ALT 2% 3% Increased AST 1% 3% Increased Creatine Phosphokinase 1% 3% Constipation 1% 2% Rhinitis 1% 2% Other Adverse Reactions Urticaria Urticaria was seen in 1.1% vs. 0% and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.
Increases in Liver Enzymes In a pooled analysis of 10 placebo controlled trials, increases to > 3 times the upper limit of normal in ALT occurred in 5.3% of patients taking either an intermediate or the maximum recommended daily dosage of fenofibrate versus 1.1% of patients treated with placebo. In an 8-week trial, the incidence of ALT or AST elevations ≥ 3 times the upper limit of normal was 13% in patients receiving an intermediate daily dosage or the maximum recommended daily dosage of fenofibrate and was 0% in those receiving the lowest recommended daily dosage of fenofibrate or placebo [see Warnings and Precautions (5.2)].
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of fenofibrate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood: Anemia, white blood cell decreases Gastrointestinal: Pancreatitis General: Asthenia Hepatobiliary: Increased total bilirubin, hepatitis, cirrhosis Immune System: Anaphylaxis, angioedema Lipid Disorders: Severely depressed HDL-cholesterol levels Musculoskeletal: Myalgia, muscle spasms, rhabdomyolysis, arthralgia Renal and Urinary: Acute renal failure Respiratory: Interstitial lung disease Skin and Subcutaneous Tissue: Photosensitivity reactions, days to months after initiation.
This may occur in patients who report a prior photosensitivity reaction to ketoprofen.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | Placebo (N =365) | Fenofibrate (N = 439) |
|---|---|---|
| Abnormal Liver Tests | 1% | 8% |
| Abdominal Pain | 4% | 5% |
| Increased ALT | 2% | 3% |
| Increased AST | 1% | 3% |
| Increased Creatine Phosphokinase | 1% | 3% |
| Constipation | 1% | 2% |
| Rhinitis | 1% | 2% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration of fenofibrate in rats and rabbits during organogenesis at doses less than or comparable to the maximum recommended clinical dosage of 150 mg daily, based on body surface area (mg/m 2).
Adverse reproductive outcomes occurred at higher doses in the presence of maternal toxicity (see Data). LIPOFEN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In pregnant rats given oral dietary doses of 14 mg/kg/day, 127 mg/kg/day, and 361 mg/kg/day from gestation day 6 to 15 during the period of organogenesis, no adverse developmental findings were observed at 14 mg/kg/day (less than the clinical exposure at the maximum recommended human dose [MRHD] of 300 mg fenofibrate daily, comparable to 150 mg LIPOFEN daily, based on body surface area comparisons).
Increased fetal skeletal malformations were observed at maternally toxic doses (361 mg/kg/day, corresponding to 12 times the clinical exposure at the MRHD) that significantly suppressed maternal body weight gain. In pregnant rabbits given oral gavage doses of 15 mg/kg/day, 150 mg/kg/day, and 300 mg/kg/day from gestation day 6 to 18 during the period of organogenesis and allowed to deliver, no adverse developmental findings were observed at 15 mg/kg/day (a dose that approximates the clinical exposure at the MRHD, based on body surface area comparisons).
Aborted litters were observed at maternally toxic doses (≥ 150 mg/kg/day, corresponding to ≥ 10 times the clinical exposure at the MRHD) that suppressed maternal body weight gain. In pregnant rats given oral dietary doses of 15 mg/kg/day, 75 mg/kg/day, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), no adverse developmental effects were observed at 15 mg/kg/day (less than the clinical exposure at the MRHD, based on body surface area comparisons), despite maternal toxicity (decreased weight gain).
Post-implantation loss was observed at ≥ 75 mg/kg/day (≥ 2 times the clinical exposure at the MRHD) in the presence of maternal toxicity (decreased weight gain). Decreased pup survival was noted at 300 mg/kg/day (10 times the clinical exposure at the MRHD), which was associated with decreased maternal body weight gain/maternal neglect.
Mechanism of action
12.1 Mechanism of Action The active moiety of LIPOFEN is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of PPAR alpha receptor.
Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol (Total-C), total triglycerides, and triglyceride rich lipoprotein (VLDL) in treated patients with severe hypertriglyceridemia.
Pharmacokinetics
In the same study, the half-life was observed to be 0.91 hours for the parent compound versus 16.76 hours for the metabolite.
Elimination Fenofibric acid is eliminated with a half-life of approximately 20 hours allowing once daily dosing of LIPOFEN.
Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine.
A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.
Excretion After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Fenofibrate is a pro-drug of the active chemical moiety fenofibric acid. Fenofibrate is converted by ester hydrolysis in the body to fenofibric acid which is the active constituent measurable in the circulation. In a study of LIPOFEN capsules 200 mg, following single-dose administration, the plasma concentration (AUC) for the parent compound fenofibrate was approximately 40 µg/mL compared to 204 µg/mL for the metabolite, fenofibric acid.
In the same study, the half-life was observed to be 0.91 hours for the parent compound versus 16.76 hours for the metabolite. Absorption The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the gastrointestinal tract.
Peak plasma levels of fenofibric acid occur within approximately 5 hours after oral administration. In a single dose and multiple dose study with LIPOFEN capsules 200 mg, the extent of absorption (AUC) of fenofibric acid, the principal metabolite of fenofibrate, was 42% larger at steady state compared to single-dose administration.
The rate of absorption (C max) of fenofibric acid was 73% greater after multiple-dose than after single-dose administration. The extent of absorption of LIPOFEN in terms of AUC value of fenofibric acid increased in a less than proportional manner while the rate of absorption in terms of C max value of fenofibric acid increased proportionally related to dose.
Effect of Food The absorption of fenofibrate is increased when administered with food. With LIPOFEN, the extent of absorption is increased by approximately 58% and 25% under high-fat fed and low-fat fed conditions as compared to fasting conditions, respectively. Distribution Upon multiple dosing of fenofibrate, fenofibric acid steady state is achieved after 5 days.
Plasma concentrations of fenofibric acid at steady state are approximately double of those following a single dose. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects. Elimination Fenofibric acid is eliminated with a half-life of approximately 20 hours allowing once daily dosing of LIPOFEN.
Metabolism Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; unchanged fenofibrate is detected at low concentrations in plasma compared to fenofibric acid over most of the single dose and multiple dosing periods. Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine.
A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine. In vitro and in vivo metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.
Excretion After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After oral administration of a single dose of radiolabeled fenofibrate in healthy volunteers, approximately 60% of the dose appeared in the urine, primarily as fenofibric acid and its glucuronide conjugate, and 25% was excreted in feces.
Use in Specific Populations Geriatric Patients In geriatric volunteers 77 to 87 years of age, the apparent oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in geriatric patients with normal renal function, without increasing accumulation of the drug or metabolites [see Dosage and Administration (2) and Use in Specific Populations (8)].
Pediatric Patients Pharmacokinetics of LIPOFEN has not been studied in pediatric patients. Male and Female Patients No pharmacokinetic difference between males and females has been observed for fenofibrate. Racial or Ethnic Groups The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability.
Patients with Renal Impairment The pharmacokinetics of fenofibric acid were examined in patients with mild, moderate and severe renal impairment. Patients with severe renal impairment (creatinine clearance [CrCl ≤30 mL/min] <30 mL/min or estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²) showed a 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects.
Patients with mild to moderate renal impairment (CrCl 30 mL/min to 80 mL/min or eGFR 30 to 59 mL/min/1.73 m²) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Patients with Hepatic Impairment No pharmacokinetic studies have been conducted in patients with hepatic impairment.
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild to moderate inhibitors of CYP2C9 at therapeutic concentrations.
Table 3 describes the effects of co-administered drugs on fenofibric acid systemic exposure. Table 4 describes the effects of co-administered fenofibrate or fenofibric acid on systemic exposure of other drugs. Table 3: Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from Fenofibrate Administration Co-Administered Drug Dosage Regimen of Co-Administered Drug Dosage Regimen of Fenofibrate Changes in Fenofibric Acid Exposure AUC C max Lipid-lowering medications Atorvastatin 20 mg once daily for 10 days Fenofibrate 160 mg TriCor (fenofibrate) oral tablet once daily for 10 days ↓2% ↓4% Pravastatin 40 mg as a single dose Fenofibrate 3 × 67 mg TriCor (fenofibrate) oral micronized capsule as a single dose ↓1% ↓2% Fluvastatin 40 mg as a single dose Fenofibrate 160 mg as a single dose ↓2% ↓10% Anti-diabetic medications Glimepiride 1 mg as a single dose Fenofibrate 145 mg once daily for 10 days ↑1% ↓1% Metformin 850 mg three times daily for 10 days Fenofibrate 54 mg three times daily for 10 days ↓9% ↓6% Rosiglitazone 8 mg once daily for 5 days Fenofibrate 145 mg once daily for 14 days ↑10% ↑3% Table 4: Effects of Fenofibrate on Systemic Exposure of Other Drugs Dosage Regimen of Fenofibrate Dosage Regimen of Co-Administered Drug Changes in Co-Administered Drug Exposure Analyte AUC C max Lipid-lowering medications Fenofibrate 160 mg TriCor (fenofibrate) oral tablet once daily for 10 days Atorvastatin, 20 mg once daily for 10 days Atorvastatin ↓17% 0% Fenofibrate 3 × 67 mg TriCor (fenofibrate) oral micronized capsule as a single dose Pravastatin, 40 mg as a single dose Pravastatin ↑13% ↑13% 3α-Hydroxyl-iso-pravastatin ↑26% ↑29% Fenofibrate 160 mg as a single dose Fluvastatin, 40 mg as a single dose (+)-3R, 5S-Fluvastatin ↑15% ↑16% Anti-diabetic medications Fenofibrate 145 mg once daily for 10 days Glimepiride, 1 mg as a single dose Glimepiride ↑35% ↑18% Fenofibrate 54 mg three times daily for 10 days Metformin, 850 mg three times daily for 10 days Metformin ↑3% ↑6% Fenofibrate 145 mg once daily for 14 days Rosiglitazone, 8 mg once daily for 5 days Rosiglitazone ↑6% ↓1%
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Fenofibrate 160 mg Tablet | ₱21.62–₱29.80Reference ₱27.50 | per tablet | DPRI procurement range |
| Fenofibrate 200 mg Capsule | ₱7.10–₱26.78Reference ₱10.87 | per capsule | DPRI procurement range |
| 160 mg tablet | ₱27.25 | per tablet | PhilHealth GAMOT fixed fee |
| 200 mg capsule | ₱15.75 | per capsule | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Fenofibrate |
| PNF listing | Oral: 200 mg capsuleRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Oral: 160 mg tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Lipofen · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 3, May 12, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78b789b9-854f-46b9-97f3-a48759a6ff89
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
